TP53 and B-cell chronic lymphocytic leukemia: The emergence of targeted compounds has rendered chemoimmunotherapy virtually obsolete for CLL treatment, with it remaining an option only for patients with a mutated IGHV, normal TP53 and a non-complex karyotype (3).